Coherus Chief: FTC Must Probe Originators’ Anti-Competitive Tactics
Executive Summary
Bundled rebate contracts for biologic brands that are designed to thwart biosimilar competition in the US are anti-competitive practices that deserve Federal Trade Commission action, biosimilar developer Coherus’ chief argues in a newspaper opinion piece.
You may also be interested in...
US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.
Coherus Fends Off Amgen’s Pegfilgrastim Purification Patent Case
Coherus’ manufacturing process for its Udenyca pegfilgrastim biosimilar does not infringe a US purification patent held by Amgen, the US Court of Appeals has confirmed.
UnitedHealthcare Coverage Policy Undercutting Neulasta Biosimilars Draws Concerns
US insurer’s commercial plans will favor the originator drug over biosimilars in return for a price concession from Amgen, while UnitedHealthcare’s Medicare Advantage plans will prefer biosimilars in several categories.